Immunodeficiency Cell Models for Research

Primary immunodeficiencies (PIDs) are a group of over 400 rare genetic disorders that impair the immune system. According to the World Health Organization (WHO), the global prevalence of PIDs is estimated at 1 in 1,000 to 1 in 500,000 depending on the specific condition. The most common forms include common variable immunodeficiency (CVID), severe combined immunodeficiency (SCID), and chronic granulomatous disease (CGD). Without treatment, many PIDs are fatal in early childhood. The NCI reports that the 5-year survival for SCID is less than 15% if untreated, but with early diagnosis and hematopoietic stem cell transplantation, survival exceeds 90%. The clinical impact is significant, with recurrent infections, autoimmunity, and increased risk of malignancies. Research into PIDs is crucial for developing gene therapies, targeted immunomodulators, and improved diagnostic tools.

PIDs are ideal for studying immune system development and function. Each PID represents a natural 'knockout' of a specific immune gene, providing unique insights into the roles of these genes in human immunity. The heterogeneity of PIDs, with over 400 genes implicated, offers a rich landscape for functional genomics. Public datasets such as the European Society for Immunodeficiencies (ESID) registry and the National Institutes of Health (NIH) Clinical Center provide extensive clinical and genetic data. Open questions include the molecular mechanisms of immune dysregulation, genotype-phenotype correlations, and the development of targeted therapies. Gene-edited cell models allow researchers to dissect these pathways in a controlled in vitro environment.

Immunodeficiency arises from defects in various immune pathways. Key pathways include:

• • T cell receptor (TCR) signaling: Defects in genes such as CD3E, ZAP70, and LCK impair T cell activation.
• • B cell receptor (BCR) signaling: Mutations in BTK, BLNK, and CD79A/B disrupt B cell development and antibody production.
• • Cytokine signaling: Defects in the common gamma chain (IL2RG), JAK3, and STAT1/STAT3 affect cytokine-mediated immune responses.
• • DNA repair and V(D)J recombination: Mutations in RAG1, RAG2, and DCLRE1C (Artemis) impair T and B cell receptor generation.
• • Innate immune signaling: Defects in TLR pathways, NADPH oxidase (CYBB), and complement components compromise pathogen clearance.

Data from TCGA and COSMIC databases.

The deregulated networks in immunodeficiency include:

• • Cytokine-JAK-STAT pathway: Key nodes include IL2RG, JAK3, STAT5B. Defects lead to impaired T cell survival and proliferation.
• • TCR signaling cascade: Key nodes include CD3, ZAP70, LAT, SLP76. Defects cause T cell anergy.
• • BCR signaling cascade: Key nodes include BTK, PLCG2, BLNK. Defects cause B cell maturation arrest.
• • DNA damage response: Key nodes include RAG1/2, Artemis, DNA-PKcs. Defects impair V(D)J recombination.
• • Innate immune signaling: Key nodes include TLRs, MyD88, IRAK4, NADPH oxidase. Defects lead to recurrent bacterial and fungal infections.

Organoid models, such as thymic organoids, are emerging as powerful tools to study T cell development and immunodeficiency. They recapitulate the 3D architecture and cellular interactions of the thymus, allowing for the study of T cell maturation and selection.

Animal models are essential for studying immunodeficiency in vivo. Examples include:

• • PDX models: Patient-derived xenografts of immunodeficient mice (e.g., NSG) engrafted with human immune cells or tumors to study immune interactions.
• • GEMMs: Genetically engineered mouse models with targeted mutations in immune genes, such as RAG1 knockout mice, which lack T and B cells.
• • Induced models: Chemical or radiation-induced immunodeficiency, such as busulfan-treated mice, to mimic conditioning regimens for transplantation.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations in immunodeficiency genes. These models are invaluable for studying gene function and drug responses. For example:

• • RAG1 knockout cell lines: Generated by CRISPR-Cas9-mediated disruption of RAG1 in a hematopoietic cell line, recapitulating the V(D)J recombination defect.
• • IL2RG knock-in cell lines: Introducing a specific point mutation (e.g., c.684C>A) into IL2RG to model X-linked SCID.
• • BTK knockout cell lines: Disrupting BTK in B cell lines to study BCR signaling.

These sequence-verified, commercially available models accelerate research by providing consistent, reproducible systems. They are essential for drug screening, functional genomics, and target validation.

Gene-edited cell lines are used to validate the function of genes implicated in immunodeficiency. For example, knocking out RAG1 in a T cell line can confirm its role in V(D)J recombination. Similarly, introducing a JAK3 mutation into a cytokine-dependent cell line can demonstrate the impact on STAT5 phosphorylation. These models allow for the dissection of signaling pathways and the identification of downstream effectors.

Isogenic pairs (wild-type vs. gene-edited) are powerful for drug screening. For instance, a BTK knockout B cell line can be used to test the specificity of BTK inhibitors. Resistance mechanisms can be studied by exposing gene-edited cells to increasing concentrations of a drug and selecting for resistant clones. This approach has been used to identify mutations in the drug target or compensatory pathways.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the context of a specific immunodeficiency mutation. For example, in a RAG1-deficient cell line, a genome-wide CRISPR screen can reveal genes whose knockout is lethal, providing potential therapeutic targets. This approach has been applied to identify vulnerabilities in cancer cells with specific mutations, and can be adapted to immunodeficiency models.